RELMADA THERAPEUTICS, INC. - 10-Q Filing
Relmada Therapeutics filed a Form 10-Q for the quarter ended March 31, 2026. The company reported a net loss of $19.05 million and a loss per share of $0.22 during the period compared to a net loss of $17.56 million ($0.58/share) in Q1 2025. Relmada incurred significant operating expenses, including research and development costs of $8.09 million and general/administrative expenses of $11.37 million. (Items: 1.01 of the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on March 9, 2026)
Tickers: $RLMD